Medimaps Group Expands in the U.S. With the Launch of TBS Osteo Next-Generation Software for Advanced Bone Microarchitecture Assessment
With its cutting-edge technology, the TBS Osteo Advanced software delivers unmatched accuracy while remaining cost-effective. Share
The TBS Osteo Advanced software delivers refined correction for soft tissue thickness anterior to the lumbar spine, ensuring inclusivity of TBS assessment across a wide range of body phenotypes. It also introduces new system management capabilities, allowing hospitals and healthcare networks to centrally manage the TBS software on their DXA systems fleet, and to standardize workflows across multiple locations. These improvements enhance operational efficiency, streamline clinical processes, and ensure consistent patient care.
TBS Osteo is available through a convenient subscription model, a flexible option providing customers with eligibility for software updates, new features and support services. This approach ensures healthcare organizations stay up to date with the latest innovations in osteoporosis care. Current TBS Osteo users have the possibility to upgrade to the next generation version and to take advantage of the new capabilities.
'With its cutting-edge technology, the TBS Osteo Advanced software delivers unmatched accuracy while remaining cost-effective. Designed for seamless integration into clinical workflows, it requires no additional exam time or extra appointments - an essential advantage for busy radiology professionals,' said Univ. Prof. Dr. Didier Hans, CEO and Co-founder of Medimaps Group. 'Its proven impact on patient care, ease of use, and its reimbursement status set it apart from competing technologies, reinforcing its presence in the vast majority of the U.S.' top-ranked hospitals.'
Since its initial launch in 2012, TBS Osteo has been widely adopted across the U.S., including by 16 of the top 20 hospitals and healthcare providers, to support the assessment and management of osteoporosis. The software is backed by over 1,400 peer-reviewed publications and endorsed by 30 national and international clinical guidelines for its use in fracture risk assessment with DXA imaging.
In the U.S., the software has received clearance from the Food and Drug Administration (FDA) and remains the only approved medical software for bone microarchitecture evaluation in clinical practice. Since 2022, Medicare has reimbursed TBS Osteo through four Category 1 CPT codes - 77089, 77090, 77091, and 77092 - offering additional reimbursement beyond standard DXA scan coverage. This recognition highlights the growing importance of comprehensive bone health assessments in the fight against osteoporosis.
Osteoporosis is a condition that weakens bones and increases the risk of fractures. According to the Bone Health & Osteoporosis Foundation (BHOF), approximately 10 million Americans have osteoporosis, while another 44 million have low bone density, putting them at risk if left untreated. In total, 54 million Americans - half of all adults aged 50 and older - are at risk of breaking a bone due to osteoporosis.
About Medimaps Group
Founded by medical practitioners and clinical researchers, Medimaps combines Swiss innovation with a global presence to lead in bone health management. We provide healthcare professionals worldwide with advanced AI-driven software that enables comprehensive bone microarchitecture assessment.
Our passion for musculoskeletal health is underpinned by scientific knowledge, collaborations with world-class academics, clinicians, industry partners, and direct patient engagement. The science behind our cutting-edge imaging applications and clinical evidence forms the core of our company's DNA.
Medimaps Group, headquartered in Geneva, Switzerland, has offices in the United States and France. Its U.S. affiliate, Medimaps Group USA LLC, markets the company products and services.
Learn more at www.medimaps.ai.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
27 minutes ago
- Newsweek
The Bulletin June 21, 2025
The rundown: The issue of animal testing is something most Americans agree on: it needs to change and gradually be stopped. Since President Donald Trump began his second term, his administration has been making moves to transform and reduce animal testing in country. Find out what steps are being taken. Why it matters: In April, the Food and Drug Administration (FDA) said that its animal testing requirement will be "reduced, refined, or potentially replaced" with a range of approaches, including artificial intelligence-based models, known as New Approach Methodologies or NAMs data. The Trump administration's efforts to tackle the issue of animal testing appear to be a step in the right direction, according to experts who spoke with Newsweek. Read more in-depth coverage: Over 300 Animals Removed From US Safari After Decade of Red Flags TL/DR: Millions of animals each year are killed in U.S. laboratories as part of medical training and chemical, food, drug and cosmetic testing. What happens now? A Department of Health and Human Services (HHS) official told Newsweek: "The agency is paving the way for faster, safer, and more cost-effective treatments for American patients.' Deeper reading How Animal Testing in US Could Be Transformed Under Trump
Business Wire
40 minutes ago
- Business Wire
Invested in America: Philip Morris International Highlights Bold Commitment to America Through New National Ad Campaign
STAMFORD, Conn.--(BUSINESS WIRE)--Today, Philip Morris International's U.S. businesses ('PMI U.S.') unveiled 'Invested in America,' a bold advertising campaign that brings to life the company's deep-rooted commitment and increased contributions to America and Americans. The campaign's message is grounded in the role PMI U.S. is playing in powering job growth, revitalizing manufacturing, improving public health by offering adults 21+ who smoke better choices, and strengthening communities across the nation. 'Philip Morris International is invested in America's future—and we have a proud story to tell,' said Stacey Kennedy, CEO of PMI U.S. 'From building our advanced manufacturing facilities to contributing to progress within communities nationwide, the people of PMI U.S. are helping to write America's next chapter. Our story is part of the story of America, unfolding from our global headquarters in Stamford, Connecticut, to our operations across America's heartland, where we will continue to create high-quality, high-paying jobs and invest in innovation for generations to come.' The ad campaign captures PMI U.S.'s vision of what responsible business leadership looks like in today's America, grounded in the places it calls home. It is rooted in concrete actions that deliver tangible benefits to American workers, communities, and the economy. The campaign will launch on July 3 with full-page print advertisements, and a corresponding digital campaign will follow. Together, the ads will introduce PMI U.S.'s vision to decision-makers and opinion leaders across the business, policy, and civic spheres, inviting them to join a coalition of stakeholders dedicated to the country's success. It will also tell the PMI U.S. story to Americans, who want to see corporations step up to the challenges they see in their lives and communities. 'Invested in America' will highlight the four pillars of PMI U.S.'s American commitment: America's Manufacturing Comeback: With announced plans to invest over $800 million in new and expanded U.S. manufacturing facilities to produce smoke-free products, PMI U.S. isn't just growing American manufacturing—it's supporting a renaissance, creating high-skilled, high-paying jobs that contribute to thriving communities. Advancing Public Health: PMI, which has never sold cigarettes in the U.S., is on a mission to help America's ~30 million legal-age adults who smoke replace combustible cigarettes—by far the most harmful way to consume nicotine—with FDA-authorized, smoke-free alternatives that are scientifically substantiated to be a better choice for adults 21+ who would otherwise smoke. Strengthening Communities: PMI U.S.'s approach to corporate citizenship involves strategic investment in communities where its employees and 21+ adult consumers live and work, focusing on sustainable impact rather than short-term interventions. It is committed to causes that matter to Americans, including supporting military veterans and their families, promoting economic empowerment, and responding to natural disasters. Purpose-Driven Performance: With $14+ billion invested globally in smoke-free innovation since 2008, PMI is driving transformative solutions while delivering strong business results. Philip Morris International is headquartered in Stamford, Connecticut, and PMI U.S. has multiple operations in Virginia, Colorado, North Carolina, and Kentucky. As it opens and expands facilities, the business is generating hundreds of high-quality jobs and millions of dollars in direct investment in communities around the country. PMI U.S. has also contributed approximately $25 million to charitable causes since 2022. In 2024 alone—the first official year of its philanthropy program—PMI U.S. and its employees contributed more than $10 million to 327 nonprofits in 35 states. 'This campaign embodies our innovation and determination to reshape an entire industry and strengthen America,' Kennedy added. 'It also reflects our commitment to meaningful investments that create genuine value for our business, our workforce, and our communities. In every state where we operate, we're not just doing business—we're creating opportunities that will define the America of tomorrow.' Invested in America Philip Morris International Inc.'s U.S. businesses (collectively, 'PMI U.S.') are on a mission to improve public health in America by providing the ~30 million legal-age consumers who still smoke traditional cigarettes with better, smoke-free alternatives. PMI U.S. is committed to responsible marketing practices that help prevent access to its products by people under the age of 21. PMI U.S. businesses employ more than 2,500 people across America and operate product manufacturing facilities, including in Owensboro, Kentucky, and Wilson, North Carolina. Since 2022, PMI U.S. has contributed approximately $25 million to charitable causes, amplifying the good work of organizations already active within communities through financial contributions and volunteering. For more information, please visit and Forward-Looking and Cautionary Statements This press release contains projections of future results and goals and other forward-looking statements, including statements regarding expected operational performance; capital expenditures; and business plans and strategies. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements. Pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, PMI is identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking statements made by PMI. PMI's business risks include: excise tax increases and discriminatory tax structures; increasing marketing and regulatory restrictions that could reduce our competitiveness, eliminate our ability to communicate with adult consumers, or ban certain of our products in certain markets or countries; health concerns relating to the use of tobacco and other nicotine-containing products and exposure to environmental tobacco smoke; litigation related to tobacco and/or nicotine use and intellectual property; intense competition; the effects of global and individual country economic, regulatory and political developments, natural disasters and conflicts; the impact and consequences of Russia's invasion of Ukraine; changes in adult smoker behavior; the impact of natural disasters and pandemics on PMI's business; lost revenues as a result of counterfeiting, contraband and cross-border purchases; governmental investigations; unfavorable currency exchange rates and currency devaluations, and limitations on the ability to repatriate funds; adverse changes in applicable corporate tax laws; recent and potential future tariffs imposed by the U.S. and other countries; adverse changes in the cost, availability, and quality of tobacco and other agricultural products and raw materials, as well as components and materials for our electronic devices; and the integrity of its information systems and effectiveness of its data privacy policies. PMI's future profitability may also be adversely affected should it be unsuccessful in its attempts to introduce, commercialize, and grow smoke-free products or if regulation or taxation do not differentiate between such products and cigarettes; if it is unable to successfully introduce new products, promote brand equity, enter new markets or improve its margins through increased prices and productivity gains; if it is unable to expand its brand portfolio internally or through acquisitions and the development of strategic business relationships; if it is unable to attract and retain the best global talent, including women or diverse candidates; or if it is unable to successfully integrate and realize the expected benefits from recent transactions and acquisitions. Future results are also subject to the lower predictability of our smoke-free products performance. PMI is further subject to other risks detailed from time to time in its publicly filed documents, including PMI's Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2024, and the Quarterly Report on Form 10-Q for the first quarter ended March 31, 2025. PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forward-looking statement that it may make from time to time, except in the normal course of its public disclosure obligations. References to 'PMI' mean the Philip Morris International family of companies. 'PMI U.S.,' 'we,' 'our,' and 'us' refer to PMI U.S. businesses.
Business Wire
an hour ago
- Business Wire
Tinnitus Research: Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model
ERLANGEN, Germany & BERLIN--(BUSINESS WIRE)--The novel compound AC102 almost completely reversed tinnitus in a preclinical model after a single dose. At the same time, the damaged connections between the auditory nerve and inner ear sensory cells were restored. These findings were recently published in the prestigious International Journal of Molecular Sciences in a joint study conducted by Erlangen University Hospital and Berlin-based drug developer AudioCure. As there is currently no causal treatment for tinnitus, there is a high medical need. AC102 regenerates connections between the inner ear and auditory nerve in a preclinical model and eliminates tinnitus. Efficacy of AC102 on sudden hearing loss and tinnitus currently investigated in clinical trial. Share In the current study, AC102 was administered to the middle ear of one experimental group after acoustic trauma, while a second group received a placebo. Although both groups initially showed signs of tinnitus, they nearly disappeared in the AC102 group after five weeks – in clear contrast to the placebo group. Additionally, the AC102 group showed significantly less loss of synaptic connections between the inner ear and the auditory nerve than the placebo group. This damage is considered to be a potential cause of tinnitus: 'Our results suggest regeneration of inner ear structures that are critical for tinnitus and could be an important milestone and a glimmer of hope for a causal treatment of tinnitus,' says the study's first author, Dr. Konstantin Tziridis from Erlangen University Hospital. About two-thirds of sudden hearing loss patients also suffer from tinnitus, which persists in around 30% of cases. Although 10-15% of adults experience tinnitus, no effective causal treatment exists. AC102 has the potential to become a new treatment option. In a preclinical acoustic trauma model, it almost completely reversed sudden hearing loss. Since tinnitus often accompanies sudden hearing loss, AudioCure is investigating AC102's potential efficacy also against tinnitus in its ongoing study. AudioCure's CEO, Dr. Reimar Schlingensiepen, emphasizes: "Constant ear noise caused by tinnitus can be even more stressful for many patients than the hearing loss itself. With AC102, we hope to eventually have an effective remedy for both conditions. This would be a great relief for patients and doctors who have no approved drug treatment available at present." AC102 has already been tested for safety and tolerability in a clinical study and is currently being examined in a Europe-wide Phase-2-study in patients for its effectiveness in sudden hearing loss and tinnitus.
